Back to top

Marrone Bio's (MBII) Venerate XC Now Available in New York

Read MoreHide Full Article

Marrone Bio Innovations, Inc. (MBII - Free Report) announced the availability of Venerate XC bioinsecticide in New York. Venerate XC, a liquid microbial-based, contact and ingestion insecticide degrades insect exoskeletons. It interferes with the molting of chewing insects, nymphs, adult sucking insects, as well as with flies and mites. This enables effective pest control.

This is Marrone Bio’s second bioinsecticide designed for pest management in New York. Notably, it is already available in other states since 2015. Venerate XC helps to control a variety of chewing and sucking insects and mites in a cost-effective manner. Grandevo, the other bioinsecticide by the company, and Venerate XC used together will enable farmers in New York to manage pests and reduce chemical residues along with lowering the risk of insecticide resistance.

Being a user-friendly liquid formulation, Venerate XC is approved for use on a variety of vegetables, fruits and crops in conventional integrated pest management and organic systems. Venerate XC boasts a zero-day pre-harvest interval and an exemption from maximum residue level tolerances, a measure of pesticide residue limits which must be met for food crop exports. It also has a minimal four hour re-entry interval.  Additionally, the product is non-toxic to fishes and birds, and is beneficial to insects like honeybees.

Marrone Bio has underperformed the industry it belongs to over a year. The company’s shares have lost around 32.9% over this period against the industry’s gain of 32%.


Marrone Bio reported a net loss of $7.4 million or 25 cents per share in second-quarter 2017, compared with a loss of $6.8 million or 28 cents per share a year ago. Loss per share for the quarter was wider than the Zacks Consensus Estimate of a loss of 21 cents.

The company, during second-quarter earnings call, announced that it is seeing above industry average growth for its products driven by its portfolio approach to product development and marketing which focuses on addressing unmet market needs and promotes substantial growth opportunities. It is gaining from efforts to grow revenues from existing as well as new products and strategic partnerships in the United States and overseas markets. The company expects its ongoing manufacturing improvement initiatives in research and development to contribute to a meaningful improvement in margins over the long term.

Marrone Bio Innovations, Inc. Price and Consensus


Zacks Rank & Key Picks

Marrone Bio currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the basic material space are The Chemours Company (CC - Free Report) , FMC Corporation (FMC - Free Report) and Air Products and Chemicals, Inc. (APD - Free Report) .

Chemours has expected long-term earnings growth of 15.5% and sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

FMC has expected long-term earnings growth of 11.3% and flaunts a Zacks Rank #1.

Air Products has expected long-term earnings growth of 12.1% and carries a Zacks Rank #2 (Buy).

Can Hackers Put Money INTO Your Portfolio?

Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.

Zacks has just released Cybersecurity! An Investor’s Guide to help readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.

Download the new report now>>

More from Zacks Analyst Blog

You May Like